Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Irwin Naturals Inc (OP: IWINF )

1.250 UNCHANGED
Last Price Updated: 1:48 PM EDT, May 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.250
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.250
Today's Range 1.250 - 1.250
52wk Range 0.8000 - 3.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Irwin Naturals FY22 Revenue Declines 10.8%, What About Adjusted EBITDA?
Irwin Naturals Inc. (OTCQB: IWINF) (CSE:IWIN) (FRA:97X) revenue in 2022 was $89.5 million, down 10.8% from $100.3 million in 2021. 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga

Performance

YTD
-51.92%
-51.92%
1 Month
-24.70%
-24.70%
3 Month
-55.36%
-55.36%
6 Month
-54.38%
-54.38%
1 Year
-34.21%
-34.21%

More News

Read More
Cannabis Scandal And Resignation Of Oregon Official, USCC's New Leadership & More Executive Moves
Via Benzinga
Psychedelics Company Confirms Shares Spinout, Another Fails To File Financials & Gets CTO Issue
Via Benzinga
Cantor Fitzgerald Discontinues Research Coverage Of The Cannabis Sector
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Via Benzinga
Irwin Naturals Cannabis Products Launch Nationwide In Canada
Via Benzinga
Irwin Naturals Acquires Ketamine Media
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Via Benzinga
In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
Via Benzinga
Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
Via Benzinga
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Via Benzinga
'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar
Via Benzinga
Irwin Naturals Secures $40M To Accelerate Expansion Of Its Psychedelic Mental Health Clinics
Via Benzinga
Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
Via Benzinga
Irwin Naturals TCH Products To Hit The Shelves Of ~2700 Dispensaries In Oklahoma Via Gold Rush
Via Benzinga
Irwin Naturals, Numinus, Field Trip: Sector Analyst Compares Footprints, Cash, Organic Growth
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Via Benzinga
Irwin Naturals To Enter Oregon Cannabis Market Via Hyphae Wellness
Via Benzinga
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.